Alteogen, ALT-B4 shares strengthen on news of European substance patent registration
Alteogen’s self-developed recombinant human hyaluronidase 'ALT-B4' saw its share price strengthen in the 10% range after news emerged that its European substance patent registration had been approved. On the same day, Labgenomics rose 13% on news of an investment by Stick Investment. Korea Investment & Securities said the Bank of Korea was highly likely to prioritize foreign-exchange policy in response to the high exchange rate.
Get free 알테오젠 email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Alteogen announced that it had received approval for the European substance patent registration of ALT-B6 month 9 day (recombinant human hyaluronidase). The company said it had also received approval for registration of a European patent related to its formulation-conversion technology. The company explained that the patent covers the substance itself and the scope of its application to formulation conversion.4},
After news of the patent registration emerged, Alteogen’s share price showed strength in the 10% range both intraday and at the close. The company said it had secured the patent registration approval document along with the related decision. The market responded immediately to the notice of allowance for the patent.
On the same day, Labgenomics’ share price surged 13% after news emerged of an investment from Stick Investment. The company disclosed the possibility of attracting investment and announced that investment-related procedures were under way. The investment amount and specific terms will be confirmed through additional disclosures.
Korea Investment & Securities said 6month 9day that, amid high exchange rates, the Bank of Korea is more likely to approach the situation through foreign-exchange policy than through a big step. This assessment points to policy choices related to exchange-rate volatility. Following the announcement of the assessment, reactions in the foreign-exchange and financial markets are being observed.
This disclosure and assessment are based on each company’s investor disclosures and securities firms’ views. Alteogen and LabGenomics reported the facts through disclosures concerning patent approval and investment, respectively. If additional related disclosures are issued, the companies will notify the market through disclosures.
The stock-market reaction and policy assessment are facts confirmed in trading that day. Investors should check the detailed information through company disclosures and any additional documents issued later. Future disclosures by each company will be posted on the exchange disclosure system.